VISTAGEN : la ricetta per la felicità da sniffare...????
- Creatore Discussione TheBigHunter
- Data di inizio
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.150
- Punti reazioni
- 1.266
La cosa positiva è che non ce ne sono
Il fatto è che sono così abituato a vedere questi pump&dump su queste piccole società che ormai quando vedo un rialzo ho il dito sul tasto sell stile "Per un pugno di dollari"
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.150
- Punti reazioni
- 1.266
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Provided by Business Wire
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder
Social anxiety disorder affects over 25 million Americans
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD).
“Initiating PALISADE-3 is another major milestone in our plan to develop and commercialize fasedienol as the first treatment of its kind for social anxiety disorder,” said Shawn Singh, Chief Executive Officer. “We look forward to initiating PALISADE-4 in the second half of this year and advancing our innovative pherine pipeline to deliver pioneering neuroscience to patients affected by mental health disorders and unsatisfied with current treatments.”
PALISADE-3, similar to PALISADE-2, is a randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the efficacy, safety, and tolerability of the acute administration of fasedienol to relieve anxiety symptoms in patients with SAD induced by a public speaking challenge conducted in a clinical setting. The primary outcome measure is the patient self-rated Subjective Units of Distress Scale (SUDS). The U.S. multi-center study is planned to randomize approximately 236 adults ages 18 through 65. Patients will be randomized in a 1:1 ratio to fasedienol or placebo. Patients who complete PALISADE-3 will have an option to enroll in an open-label extension. Vistagen plans to initiate PALISADE-4, which will be a replicate of PALISADE-3, during the second half of 2024.
About Fasedienol Nasal Spray
Vistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational pherine nasal spray with a novel proposed mechanism of action (MOA) that is differentiated from all currently approved anxiety medications, including the SSRIs and SNRI currently approved for the treatment of social anxiety disorder (SAD), as well as benzodiazepines prescribed off-label. Fasedienol’s proposed MOA regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system, without systemic distribution, potentiation of GABA-A receptors, or direct activity on neurons in the brain. Vistagen’s registration-directed PALISADE Phase 3 program for fasedienol is focused on the acute treatment of SAD. Fasedienol has not demonstrated any signals of abuse potential or physical dependence in any clinical trial conducted to date.
The U.S. FDA has granted Fast Track designation for the investigation of fasedienol for the acute treatment of SAD.
About Social Anxiety Disorder
Social anxiety disorder (SAD) affects over 25 million Americans. A person with SAD feels intense, persistent symptoms of anxiety or fear in certain social situations, such as meeting new people, making comments in a business meeting, dating, being on a job interview, answering a question in class, or talking to a cashier in a store. Doing common, everyday things in front of people causes profound anxiety or fear of being embarrassed, evaluated, humiliated, judged, or rejected. SAD can get in the way of going to work, attending school, or doing a wide variety of things in a situation that is likely to involve interpersonal interaction. It can lead to avoidance and opportunity costs that can significantly impact a person's employment and social activities and can be very disruptive to their overall quality of life. There is no FDA-approved acute, as-needed treatment for SAD. Current FDA-approved treatments for SAD include only antidepressants, which have a slow onset of effect (several weeks), provide limited therapeutic benefits, and have known side effects that may make them unattractive to individuals affected by SAD.
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Provided by Business Wire
Apr 1, 2024 2:30pm
Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Key study underway in registration-directed PALISADE Phase 3 program for fasedienol in social anxiety disorder
Social anxiety disorder affects over 25 million Americans
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it has enrolled the first patient in its PALISADE-3 Phase 3 trial of fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder (SAD).
“Initiating PALISADE-3 is another major milestone in our plan to develop and commercialize fasedienol as the first treatment of its kind for social anxiety disorder,” said Shawn Singh, Chief Executive Officer. “We look forward to initiating PALISADE-4 in the second half of this year and advancing our innovative pherine pipeline to deliver pioneering neuroscience to patients affected by mental health disorders and unsatisfied with current treatments.”
PALISADE-3, similar to PALISADE-2, is a randomized, double-blind, placebo-controlled Phase 3 study designed to evaluate the efficacy, safety, and tolerability of the acute administration of fasedienol to relieve anxiety symptoms in patients with SAD induced by a public speaking challenge conducted in a clinical setting. The primary outcome measure is the patient self-rated Subjective Units of Distress Scale (SUDS). The U.S. multi-center study is planned to randomize approximately 236 adults ages 18 through 65. Patients will be randomized in a 1:1 ratio to fasedienol or placebo. Patients who complete PALISADE-3 will have an option to enroll in an open-label extension. Vistagen plans to initiate PALISADE-4, which will be a replicate of PALISADE-3, during the second half of 2024.
About Fasedienol Nasal Spray
Vistagen’s fasedienol (PH94B) is a first-in-class, rapid-onset investigational pherine nasal spray with a novel proposed mechanism of action (MOA) that is differentiated from all currently approved anxiety medications, including the SSRIs and SNRI currently approved for the treatment of social anxiety disorder (SAD), as well as benzodiazepines prescribed off-label. Fasedienol’s proposed MOA regulates the olfactory-amygdala neural circuits of fear and anxiety and attenuates the tone of the sympathetic autonomic nervous system, without systemic distribution, potentiation of GABA-A receptors, or direct activity on neurons in the brain. Vistagen’s registration-directed PALISADE Phase 3 program for fasedienol is focused on the acute treatment of SAD. Fasedienol has not demonstrated any signals of abuse potential or physical dependence in any clinical trial conducted to date.
The U.S. FDA has granted Fast Track designation for the investigation of fasedienol for the acute treatment of SAD.
About Social Anxiety Disorder
Social anxiety disorder (SAD) affects over 25 million Americans. A person with SAD feels intense, persistent symptoms of anxiety or fear in certain social situations, such as meeting new people, making comments in a business meeting, dating, being on a job interview, answering a question in class, or talking to a cashier in a store. Doing common, everyday things in front of people causes profound anxiety or fear of being embarrassed, evaluated, humiliated, judged, or rejected. SAD can get in the way of going to work, attending school, or doing a wide variety of things in a situation that is likely to involve interpersonal interaction. It can lead to avoidance and opportunity costs that can significantly impact a person's employment and social activities and can be very disruptive to their overall quality of life. There is no FDA-approved acute, as-needed treatment for SAD. Current FDA-approved treatments for SAD include only antidepressants, which have a slow onset of effect (several weeks), provide limited therapeutic benefits, and have known side effects that may make them unattractive to individuals affected by SAD.
A metà marzo avevo la possibilità di rientrare sotto i 4 e mi sono fatto fregare..quel pomeriggio di inizio Agosto 2023 resta indimenticabile
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.150
- Punti reazioni
- 1.266
È si, è stata una grandissima botta di kiulo
beppofinanza
Nuovo Utente
- Registrato
- 7/1/21
- Messaggi
- 876
- Punti reazioni
- 48
Che giornata … che gain…
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.150
- Punti reazioni
- 1.266
Con sogno premonitore la notte prima
Che ricordi
beppofinanza
Nuovo Utente
- Registrato
- 7/1/21
- Messaggi
- 876
- Punti reazioni
- 48
Chissà che ricapita ancora ..
BigNick
Siamo solo noi
- Registrato
- 10/7/01
- Messaggi
- 12.150
- Punti reazioni
- 1.266